ArticleScientific reports2025
hERG toxicity prediction in early drug discovery using extreme gradient boosting and isometric stratified ensemble mapping.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Cardiosim-Tox: an interpretable multitask deep learning QSAR platform with multimodal feature fusion for predicting hERG, Cav1.2, and Nav1.5 blockade risk and potency.Archives of toxicology · 2026Article
- Article
- Review
- HERGAI: an artificial intelligence tool for structure-based prediction of hERG inhibitors.Journal of cheminformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blockade of the human Ether-à-go-go Related Gene (hERG) potassium channel by small molecules can prolong the QT interval, leading to fatal cardiotoxicity. Numerous drugs have been withdrawn from the market due to cardiac side effects, underscoring the need for early identification of hERG toxicity. Despite several classification machine learning (ML) models having been developed to this end, robustness, class imbalance, and interpretability are still challenges. Using the largest public database of hERG inhibition, this work integrates eXtreme Gradient Boosting (XGBoost) with Isometric Stratified Ensemble (ISE) mapping (XGB + ISE map) to enhance hERG prediction. An XGBoost consensus model was developed using balanced training sets and diverse variable subsets, resulting in robust models less affected by class imbalance. The model demonstrated competitive predictive performance, achieving a balance between sensitivity (SE = 0.83) and specificity (SP = 0.90) through exhaustive validation. ISE mapping estimated the model applicability domain and improved prediction confidence evaluation and compound selection by stratifying data. Refined variable selection procedures enhanced model interpretability. Variable importance analysis highlights key molecular determinants (peoe_VSA8, ESOL, SdssC, MaxssO, nRNR2, MATS1i, nRNHR, nRNH2) associated with hERG inhibition. The XGB + ISE map strategy provides an effective approach to identifying promising molecules in drug discovery campaigns with reduced hERG inhibition risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.